AU2012201823A1 - Treatment of inflammatory conditions of the intestine - Google Patents

Abstract

C:NRPonblDCAMC\4225446_1 DOC-21/20I2 A method for the treatment and/or prophylaxis of an inflammatory condition of the intestine of a patient, such as ischaemia/reperfusion (1/R) injury of the intestine, inflammatory bowel disease, acute infective colitis, or pseudomembranous colitis, comprises parenteral administration to the patient of an effective amount of high density lipoprotein (HDL).

Description

Australian Patents Act 1990 - Regulation 3.2 ORIGINAL COMPLETE SPECIFICATION STANDARD PATENT Invention Title "Treatment of inflammatory conditions of the intestine" The following statement is a full description of this invention, including the best method of performing it known to us:- C:NRPonbl\DCC\AMC\4225446_J DOC-21/3(212 TREATMENT OF INFLAMMATORY CONDITIONS OF THE INTESTINE This application is a divisional of Australian Patent Application No. 2005201035, the entire contents of which is incorporated herein by reference. 5 FIELD OF THE INVENTION This invention relates generally to a method for the treatment and/or prophylaxis of inflammatory conditions of the intestine, including but not limited to inflammation and inflammatory damage 10 associated with ischaemia/reperfusion injury of the intestine, inflammatory bowel disease and colitis. More particularly, the present invention relates to the use of high density lipoproteins (HDLs) in the treatment and/or prophylaxis of these inflammatory conditions of the intestine. BACKGROUND OF THE INVENTION 15 Bibliographic details of the publications referred to in this specification are referenced at the end of the description. The reference to any prior art document in the specification is not, and should not be taken as, an acknowledgment or any form of suggestion that the document forms part of the common general knowledge in Australia. 20 High-density lipoproteins (HDLs) represent a broad group of mostly spheroidal plasma lipoproteins, which exhibit considerable diversity in their size, apolipoprotein (apo) and lipid composition. HDL particles fall into the density range of 1.063-1.21 g/ml (1) and as they are smaller than other lipoproteins, HDLs can penetrate between endothelial cells more readily allowing relatively high 25 concentrations to accumulate in tissue fluids (2). The major apolipoprotein of almost all plasma HDLs is apo A-1, which in association with phospholipids and cholesterol, encloses a core of cholesteryl esters (1). Nascent (i.e. newly synthesised) HDLs secreted by the liver and intestine contain no cholesteryl esters and are discoidal in shape (1). The negative association of plasma HDL concentration with coronary artery disease has been well documented in epidemiological studies (3). 30 Although experiments in animals have demonstrated an anti-atherogenic activity of HDLs (4), it is not yet known whether this protective effect is related to the role of the lipoprotein in reverse cholesterol C:\NRPonbRCC\AMC4225446_. DOC-2 /112012 -2 transport or to a different mechanism. The mechanism/mechanisms via which HDLs provide these cardioprotective actions are not clearly understood, but may include a role for HDLs in reverse transport of cholesterol from peripheral tissues to the liver, inhibition of the oxidation of low-density lipoproteins, or modulation of vasodilatation and platelet activation mediated by changes in the 5 production of prostacyclin (5). HDLs can also activate endothelial nitric oxide synthase subsequent to its interaction with scavenger receptor-B1 (SR-B1). Although HDLs are involved in the removal of cholesterol from extra-hepatic tissues, this subset of lipoproteins has recently been reported to possess functions unrelated to their role in plasma cholesterol transport. Almost 10 years ago, it was reported that in transgenic mice in which plasma levels of HDL were two-fold higher, the increase in 10 plasma levels of TNF-a as well as mortality caused by bacterial lipopolysaccharide (LPS) were significantly reduced (6). Subsequently, it has been demonstrated that administration of native HDL or reconstituted HDL (=recHDL) significantly reduces organ injury and levels of mortality in animal models of endotoxic (LPS-mediated) and haemorrhagic shock (7). The beneficial actions observed in these models are - at least in part - mediated by the ability of HDLs to bind and inactivate LPS (6,8), directly 15 inhibit expression of adhesion molecules on endothelial cells and via modulation of the expression of proinflammatory cytokines (6,9). In human volunteers, systemic administration of HDLs also downregulates the LPS ligand CD14 on monocytes and attenuates the release of TNF-a, IL-6 and IL-8 caused by small doses of intravenously administered LPS (10). HDL has also been shown to directly inhibit the TNF-a-induced expression of P-selectin on human endothelial cells (6). In addition, it has 20 been reported that HDLs reduces the renal injury, dysfunction and inflammation caused by bilateral renal artery occlusion and reperfusion in the rat (11). A growing body of data indicates that oxygen-derived free radicals such as superoxide (02-), nitric oxide (NO) and hydroxyl radicals (OH-) have a role in mediating the intestinal damage in 25 ischaemia/reperfusion [I/R] (12,13) as well as in inflammatory bowel disease (IBD) (14). The intestine is well endowed with enzymes capable of producing such free radicals (15). Moreover, when inflammation is present the many phagocytic cells that are attracted and activated can produce large amounts of free radicals. Several studies suggest that peripheral blood monocytes (16), and isolated intestinal macrophages (17), from patients with IBD produce increased amounts of free radicals. Also 30 high numbers of peripheral polymorphonuclear leukocytes (PMNs), which are capable of producing large amounts of oxygen-derived free radicals (18), migrate into the intestinal wall of such patients C:\NRPorbl\DCCAMC\4225446_ IDOC-2/0312012 -3 (19). Grisham and Granger (20) hypothesised that -like in 1/R injury - in ulcerative colitis transient ischaemic and subsequent reperfusion produce high levels of free radicals. This process initiates a cascade of events leading to the recruitment and activation of PMNs. In the last few years, various studies have gained substantial insight into the importance of specific adhesion molecules and 5 mediators in processes, which finally result in the recruitment of PMNs at a specific site of inflammation. Activated PMNs, therefore, play a crucial role in the destruction of foreign antigens and the breakdown and remodelling of injured tissue. PMN-endothelial interactions involve a complex interplay among adhesion glycoproteins (i.e. integrins, members of the immunoglobulin superfamily and selectins). The firm adhesion of PMNs to the endothelium, however, is a complex phenomenon, 10 which also involves other endothelium-based adhesion molecules. In fact, endothelial adhesion molecules are considered to play a pivotal role in the localisation and development of an inflammatory reaction (21). Intercellular adhesion molecule-1 (ICAM-1) is an adhesion molecule normally expressed at a low basal level, but its expression can be enhanced by various inflammatory mediators such as TNF-a and IL-1 P (22). 15 Models of splanchnic artery occlusion shock (SAO) and 2,4,6-dinitrobenzene-sulfonic acid (DNBS) induced colitis have been widely employed to investigate the pathophysiology of intestinal damage associated with 1/R and with IBD. In work leading to the present invention, the inventors have investigated whether recHDL reduces the intestinal injury and inflammation caused by SAO shock and 20 the chronic inflammatory response (colitis) caused by injection of DNBS in the rat. In order to highlight the possible mechanisms through which HDLs confer protection, the following endpoints of the inflammatory response have been determined: (1) PMN infiltration (determined as myeloperoxidase (MPO] activity, (2) pro-inflammatory cytokine production, (3) expression of adhesion molecules (i.e. ICAM-1), (4) lipid peroxidation (evaluated as malondialdehyde (MDA] levels) (5) peroxynitrite 25 formation, (6) activation of the nuclear enzyme poly (ADP-ribose) (PAR) polymerase (PARP) and (7) morphological changes in the intestine. SUMMARY OF THE INVENTION 30 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and or variations such as "comprises" or "comprising", will be understood to imply the C kNRPotbN)CC\AMC4225446_IDOC.-2103/2112 -4 inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. In one aspect, the present invention provides a method for the treatment and/or prophylaxis of an 5 inflammatory condition of the intestine of a patient, which comprises parenteral administration to the patient of an effective amount of high density lipoprotein (HDL). In another aspect, the present invention provides the use of high density lipoprotein (HDL) in the manufacture of a medicament for parenteral administration to a patient for the treatment and/or 10 prophylaxis of an inflammatory condition of the intestine of the patient. In yet another aspect, the invention provides an agent for parenteral administration in the treatment and/or prophylaxis of an inflammatory condition of the intestine of a patient, which comprises high density lipoprotein (HDL). 15 BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows the effect of HDL treatment on mean blood pressure and survival. Effect of HDL treatment on MAP (A) and mortality (B). No significant alteration of MAP was observed in 20 sham-operated rats. Fall in MAP and the mortality in SAO rats was significantly reduced by HDL treatment (80 mg/kg). Values are means S.E.M. of 10 rats for each group. *P<0.01 versus sham, 'P<0.01 versus 1/R. Fig. 2 shows MDA and MPO tissue levels. Reperfusion of the ischaemic splanchnic circulation leads 25 to profound increase in MDA levels (A) and in MPO (B) in ileum tissues which is inhibited by HDL treatment (80 mg/kg). Values are means S.E.M. of 10 rats for each group. *P<0.01 versus sham, *P<0.01 versus 1/R. Fig. 3 shows plasma levels of TNF-a and IL-1p. Reperfusion of the ischaemic splanchnic circulation 30 leads to profound increase in plasma TNFa and IL-1p production and this is inhibited by HDL (80mg/kg). Values are means S.E.M. of 10 rats for each group. *P<0.01 versus sham, C\NRPonbNDCC\AMC4225446. I DOC-21/0/21 12 -5 *P<0.01 versus I/R. Fig. 4 shows immunohistochemical staining of ICAM-1. I/R induced an increase of the positive staining for ICAM-1 along the endothelium wall (A). In HDL-treated rats (B) subjected to SAO 5 shock, there was no increase of immunostaining for ICAM-1, which was present only along the endothelium wall. Original magnification: x 500. Figure is representative of at least 3 experiments performed on different experimental days. Fig. 5 shows typical Densitometry evaluation. Densitometry analysis of Immunocytochemistry 10 photographs (n=5) for ICAM-1, nitrotyrosine and PAR from ileum (A) and from colon (B) was assessed. The assay was carried out by using Optilab Graftek software on a Macintosh personal computer (CPU G3-266). Data are expressed as % of total tissue area. *P<0.01 versus Sham. *P<0.01 versus IR or versus DNBS. 15 Fig. 6 shows immunohistochemical staining of nitrotyrosine and PAR. After reperfusion nitrotyrosine (A) and PAR (C) staining was localised in the injured area from a SAO-shocked rat. There was no detectable immunostaining for nitrotyrosine (B) and PAR (D) in the ileum from HDL-treated rats. Original magnification: x 500. Figure is representative of at least 3 experiments performed on different experimental days. 20 Fig. 7 shows the effect of HDL treatment on the tissue damage. Distal ileum section from SAO shocked-rats showed inflammatory cell infiltration extending through the wall and concentrated below the epithelial layer and demonstrating oedema of the distal portion of the villi (A). Distal ileum from HDL-treated rats (B) shows reduced SAO-induced organ injury. Original 25 magnification: x 125. Figure is representative of at least 3 experiments performed on different experimental days. Fig. 8 shows the effect of HDL treatment on the damage score and on colon injury. Colonic damage (A) was scored on a 0 (normal) to 10 (severe) scale by two independent observers. 30 Histological examination of descending colon from DNBS-treated rats (B) reveals a complete alteration of the epithelial layer, muscularis mucosa and submucosal as well as a diffuse C:NRPortblDCC\AMC422544_L DOC-2 1/01V21112 -6 inflammatory cells infiltration in perilesional area. Treatment with HDL (C) significantly reduced the damage score (A) and corrected the disturbances in morphology and reduced the inflammatory cells infiltration associated with DNBS administration. Original magnification: x100. Figure is representative of at least 3 experiments performed on different experimental 5 days. Values are means S.E.M. of 10 rats for each group. *P<0.01 vs. sham; *P<0.01 vs. DNBS. Fig. 9 shows organ weight. A significant increase was consistently seen at 4 days after DNBS injection in colon (A) and spleen (B). The weight of the organs was significantly reduced in the 10 rats which had been treated with HDL. Values are means±s.e. means of 10 rats for each group. *p<0.01 vs. sham; *p<0.01 vs. DNBS. Fig. 10 shows the effect of HDL treatment on body weight changes and TNF-a and IL-1s levels at 4 days after DNBS intracolonic administration. A significant loss of body weight (A) and an 15 increase of TNF-a and IL-1B (B) were observed in the DNBS-treated rats. HDL treatment significantly prevented the loss of body weight and reduced the increase of cytokine levels in the colon. Values are means S.EM. of 10 rats for each group. *P<0.01 vs. sham; *P<0.01 vs. DNBS. 20 Fig. 11 shows immunohistochemical localisation for nitrotyrosine and for poly (ADP-ribose) in the colon. Immunohistochemical for nitrotyrosine (A) and for poly (ADP-ribose) (C) show positive staining primarily localised in the infiltrated inflammatory cells and in disrupted epithelial cells from a DNBS treated rats. The intensity of the positive staining for nitrotyrosine (B) and for poly (ADP-ribose) (D) was significantly reduced in the colon from HDL-treated rats. Original 25 magnification: x 250. Figure is representative of at least 3 experiments performed on different experimental days. Fig. 12 shows the effect of HDL on neutrophil infiltration and lipid peroxidation. Malondialdehyde (MDA) (A) and myeloperoxidase (MPO) activity (B) in the colon from DNBS-treated rats. MPO 30 activity and MDA levels were significantly increased in DNBS-treated rats in comparison to sham. HDL-treated rats show a significant reduction of MPO activity and MDA levels. Values C.\RPonbl\DCC\AMC'4225446I DOC-21I/3/2012 -7 are means±s.e. means of 10 rats for each group. *p<0.01 vs. sham; *p<0.01 vs. DNBS. Fig. 13 shows immunohistochemical localisation of ICAM-1 in the colon. Colon section obtained from DNBS-treated rats showed intense positive staining for ICAM-1 (A) on the vessels as well as 5 in inflammatory cells concentrated below the epithelial layer. The degree of positive staining for ICAM-1 (B) was markedly reduced in tissue section obtained from HDL-treated rats. Original magnification: x250. Figure is representative of at least 3 experiments performed on different experimental days. 10 DETAILED DESCRIPTION OF THE INVENTION High-density lipoproteins (HDLs) have been shown to reduce the organ injury and mortality in animal models of shock by reducing the expression of adhesion molecules and pro-inflammatory enzymes. However, there is limited evidence that HDL treatment reduces inflammation. As inflammation plays an 15 important role in the development of colitis as well as ischaemia/reperfusion (1/R) injury of the intestine, the inventors have investigated the effects of HDL in animal models associated with gut injury and inflammation [splanchnic artery occlusion (SAO) shock and dinitrobenzene sulfonic acid (DNBS) induced colitis], and shown that the administration of reconstituted HDL (recHDL) (80 mg/kg i.v. bolus 30 min prior ischaemia in the SAO-shock model or 40 mg/kg i.v. every 24 h in the colitis model) exerts 20 potent anti-inflammatory effects (e.g. reduced inflammatory cell infiltration and histological injury, and delayed the development of the clinical signs) in vivo. Furthermore, recHDL reduced (i) the staining for nitrotyrosine and poly (ADP-ribose) (immunohistochemistry) and; (ii) the expression of intercellular adhesion molecule-1 in the ileum of SAO-shocked rats and in the colon from DNBS-treated rats. Thus, recHDL reduces the inflammation caused by intestinal /R and colitis. 25 In one aspect, the present invention provides a method for the treatment and/or prophylaxis of an inflammatory condition of the intestine of a patient, which comprises parenteral administration to the patient of an effective amount of high density lipoprotein (HDL). 30 Reference herein to "treatment" or "prophylaxis" is to be considered in its broadest context. The term "treatment" does not necessarily imply that a subject is treated until total recovery. Similarly, C:\NRPortbhDCC\.AMCu4225446_ I DOC-21/03/2012 -8 "prophylaxis" does not necessarily mean that the subject will not eventually contract a disease condition. Accordingly, treatment and prophylaxis include amelioration of the symptoms of a particular condition or preventing or otherwise reducing the risk of developing a particular condition. The term "prophylaxis" may be considered as reducing the severity or onset of a particular condition. 5 "Treatment" may also reduce the severity of an existing condition. Inflammatory conditions of the intestine to which the present invention relates include, but are not limited to, inflammation and inflammatory damage associated with ischaemia/reperfusion (I/R) injury of the intestine, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), acute 10 infective colitis, and pseudomembranous colitis (an antibiotic-induced condition caused by Clostridium overgrowth). Such diseases are described in relevant standard textbooks which include Harrison's Principles of Internal Medicine, Oxford Textbook of Medicine, and Principles and Practice of Gastroenterology and Hepatology. 15 In accordance with the present invention, HDL is administered to a patient. The term "HDL" as used herein relates to all forms of high density lipoproteins and includes nascent HDL or reconstituted HDL (RHDL) or any mixture thereof, as well as recombinant HDL or an analogue thereof with functional relationship to nascent or reconstituted HDL. Such analogues include functional peptides derived from the apolipoprotein (Apo) structure such as those described in International Patent Publications Nos. 20 WO 99/16459 and WO 99/16408, the contents of which are incorporated herein by reference. The high density lipoproteins comprise a protein component, and lipid. The proteins are preferably apolipoproteins, e.g. human apolipoproteins such as apolipoprotein A-1 (apoA-l) or apolipoprotein A-Il (apoA-lI) or recombinant apolipoproteins, or functionally homologous peptides with similar properties. 25 Suitable lipids are phospholipids, preferably phosphatidyl choline, optionally mixed with other lipids (cholesterol, cholesterol esters, triglycerides, or other lipids). The lipids may be synthetic lipids, naturally occurring lipids or combinations thereof. Production of reconstituted HDL is described, by way of example, in US Patent No. 5652339 and by 30 Matz and Jonas (24) and Lerch et al. (25). Production of recombinant HDL is described, by way of example, in European Patent No. EP 469017 (in yeast), US Patent No. 6559284 (in E. coli), and C.\NRPortb\DCC\AMC'422544_ I DOC-21/013/2(112 -9 International Patent Publications Nos. WO 87/02062 (in E. coli, yeast and Cho cells) and WO 88/03166 (in E. coli). The contents of each of these documents are incorporated herein by reference. Preferably, the HDL is reconstituted HDL. 5 The HDL is administered in an effective amount. An "effective amount" means an amount necessary at least partly to attain the desired response, or to delay the onset or inhibit progression or halt altogether, the onset or progression of the particular condition being treated. The amount varies depending upon the health and physical condition of the individual to be treated, the racial background 10 of the individual to be treated, the degree of protection desired, the formulation of the composition, the assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Preferred HDL dosage ranges are from 0.1-200 mg, more preferably 10-80 mg, HDL (weight based on 15 apolipoprotein) per kg body weight per treatment. For example, the dosage of HDL which is administered may be about 0.2-100 mg HDL per kg body weight (weight based on apolipoprotein) given as an intravenous injection and/or as an infusion for a clinically necessary period of time, e.g. for a period ranging from a few minutes to several hours, e.g. up to 24 hours. If necessary, the HDL administration may be repeated one or several times. The actual amount administered will be 20 determined both by the nature of the disease which is being treated and by the rate at which the HDL is being administered. Preferably, the patient is a human, however the present invention extends to treatment and/or prophylaxis of other mammalian patients including primates, livestock animals (e.g. sheep, pigs, cattle, 25 horses, donkeys), laboratory test animals (e.g. mice, rabbits, rats, guinea pigs), companion animals (e.g. dogs, cats) and captive wild animals. In accordance with the present invention, the HDL is administered to a patient by a parenteral route of administration. Parenteral administration includes any route of administration that is not through the 30 alimentary canal (that is, not enteral), including administration by injection, infusion and the like. Administration by injection includes, by way of example, into a vein (intravenous), an artery C NRPonbrDCC\AMC\422546_ I DOC-2 1/3/2012 - 10 (intraarterial), a muscle (intramuscular) and under the skin (subcutaneous). The HDL may also be administered in a depot or slow release formulation, for example, subcutaneously, intradermally or intramuscularly, in a dosage which is sufficient to obtain the desired pharmacological effect. 5 Compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active component which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example 10 as a solution in a polyethylene glycol and lactic acid. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conveniently employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. 15 The formulation of such therapeutic compositions is well known to persons skilled in this field. Suitable pharmaceutically acceptable carriers and/or diluents include any and all conventional solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for 20 pharmaceutically active substances is well known in the art, and it is described, by way of example, in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Pennsylvania, USA. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the pharmaceutical compositions of the present invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions. 25 Other delivery systems can include sustained release delivery systems. Preferred sustained release delivery systems are those which can provide for release of the active component of the invention in sustained release pellets or capsules. Many types of sustained release delivery systems are available. These include, but are not limited to: (a) erosional systems in which the active component is contained 30 within a matrix, and (b) diffusional systems in which the active component permeates at a controlled rate through a polymer.

C\NRPonbnDCC\AMC%225446_ I DOC-21/01/2112 - 11 The present invention also provides the use of high density lipoprotein (HDL) in the manufacture of a medicament for parenteral administration to a patient for the treatment and/or prophylaxis of an inflammatory condition of the intestine of the patient. 5 In yet another aspect, the invention provides an agent for parenteral administration in the treatment and/or prophylaxis of an inflammatory condition of the intestine of a patient, which comprises high density lipoprotein (HDL). 10 The present invention is further illustrated by the following non-limiting Examples. EXAMPLES Materials and Methods 15 Animals Male Sprague-Dawley rats (300-350 g; Charles River; Milan; Italy) were housed in a controlled environment and provided with standard rodent chow and water. Animal care was in compliance with Italian regulations on protection of animals used for experimental and other scientific purpose (D.M. 116192) as well as with the EEC regulations (O.J. of E.C. L 358/1 12/18/1986). 20 Experimental groups (Colitis Study) Upon completion of surgical procedures, rats were randomly allocated into the following four groups: (i) DNBS + saline group; rats were given DNBS (100 mg/kg, i.c.) (N = 10), (ii) DNBS + recHDL group; rats were subjected to identical procedures as above and administered recHDL (40 mg/kg/day, i.v.) for 3 25 days (N = 10), (iii) Sham + saline group; (sham-operated) rats were subjected to identical procedures as above except that the vehicle alone (50% ethanol, 0.8 ml) was injected instead of DNBS and were maintained under anaesthesia for the duration of the experiment (N = 10), (vi) Sham + HDL group; identical to sham-operated rats except for the administration of recHDL (40 mg/kg/day, i.v.) (N = 10). The dose of recHDL used in the present study was taken from previous studies showing efficacy in 30 models of renal 1/R injury (11).

C:\NRPortbnDCC\AMC\4225446_ I DO.21/1/21)12 - 12 Experimental groups (SAO Study) Upon completion of surgical procedures, rats were randomly allocated into the following four groups: (i) I/R + saline group; rats were subjected to SAO shock (45 min) followed by reperfusion (6 h) (N = 10), (ii) I/R + rec HDL group; rats were subjected to identical surgical procedures as above and 5 administered recHDL (80 mg/kg, i.v.) 30 min prior to commencement of 1/R (N = 10), (iii) Sham + saline group; (sham-operated) rats were subjected to identical surgical procedures except for SAO shock and were maintained under anaesthesia for the duration of the experiment (N = 10), (vi) Sham + recHDL group; identical to sham-operated rats except for the administration of recHDL (80 mg/kg, i.v.) 30 min prior to commencing 1/R (N = 10). 10 Induction of Experimental Colitis Colitis was induced by using a technique of acid-induced colon inflammation as described previously (23). In fasted rats lightly anaesthetised with isoflurane, a 3.5 F catheter was inserted into the colon via the anus until approximately the splenic flexure (8 cm from the anus). DNBS (100 mg/kg i.c.) was 15 dissolved in 50% ethanol (total volume, 0.8 ml). Thereafter, the animals were kept for 15 minutes in a Trendelenburg position to avoid reflux. After colitis and sham-colitis induction, the animals were observed for 3 days. On Day 4, the animals were weighed and anaesthetised with chloral hydrate (400 mg/kg, i.p.), and the abdomen was opened by a midline incision. The colon was removed, freed from surrounding tissues, opened along the antimesenteric border, rinsed, weighed, and processed for 20 histology and immunohistochemistry. The macroscopic damage score, according to Wallace et al. (23) was assessed. Splanchnic artery occlusion shock (SAO-shock) Male Sprague-Dawley rats were anaesthetised with sodium pentobarbital (45 mg/kg, i.p.). Following 25 anaesthesia, catheters were placed in the carotid artery and jugular vein as described previously (13). Blood pressure was monitored continuously by a Maclab AID converter (AD Instruments), and stored and displayed on a Macintosh personal computer. After midline laparotomy, the celiac and superior mesenteric arteries were isolated near their aortic origins. During this procedure, the intestinal tract was maintained at 37 *C by placing it between gauze pads soaked with warmed 0.9% NaCl solution. 30 C:NRortb\DCC\AMC4225446_1 DOC-21/l321112 - 13 Rats were observed for a 30 min stabilisation period before either splanchnic ischaemia or sham ischaemia. SAO shock was induced by clamping both the superior mesenteric artery and the celiac trunk, resulting in a total occlusion of these arteries for 45 min. After this period of occlusion, the clamps were removed. In one study, the various groups of rats were sacrificed 60 min after the 5 commencement of reperfusion for histological examination of the bowel and for biochemical studies, as described below. In another set of studies, the various groups of rats were observed for 6 h following reperfusion in order to determine survival differences. Reconstituted High Density Lipoprotein (recHDL). 10 The discoidal recHDLs were provided by ZLB-Bioplasma, Bern, Switzerland. The particles, containing human apo A-1 as the sole protein and soybean phosphatidylcholine as the sole phospholipid were prepared using cholate dialysis (24). Their physicochemical properties have been described in detail (25). 15 Light Microscopy Ileum was collected after 1h of reperfusion from the rats subjected to SAO shock. The colon was collected 4 days after DNBS administration. After fixation for 1 week at room temperature in Dietrich solution (14.25% ethanol, 1.85% formaldehyde, 1% acetic acid), samples were dehydrated in graded ethanol and embedded in Paraplast (Sherwood Medical, Mahwah, New Jersey). Thereafter, 7-mm 20 sections were deparaffinized with xylene, stained with haematoxylin-eosin and trichromic van Giesson's stain, and observed in a Dialux 22 Leitz (Wetziar, Germany) microscope. Colon damage was scored by two independent observers as described previously (26), according to the following morphological criteria: 0, no damage; 1, localised hyperaemia without ulcers; 2, linear ulcers with no significant inflammation; 3, linear ulcers with inflammation at one site; 4, two or more major sites of 25 inflammation and ulceration extending >1 cm along the length of the colon; and 5-8, one point is added for each centimetre of ulceration beyond an initial 2 cm. Immunohistochemical localisation for ICAM-1, nitrotyrosine and poly (ADP-ribose) (PAR). At the specified time, the ileum and the colon tissues were fixed in 10% (w/v) phosphate buffered 30 saline (PBS)-buffered formaldehyde and 8 pm sections were prepared from paraffin embedded tissues. After deparaffinization, endogenous peroxidase was quenched with 0.3% (v/v) hydrogen C:\NRPorbl\DCC\AMC225446_1.DOC-2011/212 - 14 peroxide in 60% (v/v) methanol for 30 min. The sections were permeablised with 0.1% (w/v) Triton X 100 in PBS for 20 min. Non-specific adsorption was minimised by incubating the sections in 2% (v/v) normal goat serum in PBS for 20 min. Endogenous biotin or avidin binding sites were blocked by sequential incubation for 15 min with biotin and avidin (DBA, Milan, Italy), respectively. Sections were 5 incubated overnight with anti-nitrotyrosine rabbit polyclonal antibody (1:500 in PBS, v/v) or with anti poly (ADP-ribose) goat polyclonal antibody (1:500 in PBS, v/v) or with mouse anti-rat antibody directed at ICAM-1 (CD54) (1:500 in PBS, v/v) (DBA, Milan, Italy). Sections were washed with PBS, and incubated with secondary antibody. Specific labelling was detected with a biotin-conjugated goat anti rabbit IgG and avidin-biotin peroxidase complex (DBA, Milan, Italy). To verify the binding specificity for 10 ICAM-1 and PAR, some sections were also incubated with primary antibody only (no secondary antibody) or with secondary antibody only (no primary antibody). In these situations, no positive staining was found in the sections indicating that the immunoreactions were positive in all the experiments carried out. In order to confirm that the immunoreactions for the nitrotyrosine were specific some sections were also incubated with the primary antibody (anti-nitrotyrosine) in the presence of 15 excess nitrotyrosine (10mM) to verify the binding specificity. Immunocytochemistry photographs (N=5) were assessed by densitometry as previously described (27) by using Optilab Graftek software on a Macintosh personal computer. Myeloperoxidase (MPO) activity 20 MPO activity, an indicator of PMN accumulation, was determined as previously described (28). At the specified time point the ileum and the colon were removed and weighed. The tissues were homogenised in a solution containing 0.5% hexa-decyl-trimethyl-ammonium bromide and 10 mM 3-(N morpholino)-propane-sulfonic acid dissolved in 80 mM sodium phosphate buffer (pH 7), and centrifuged for 30 min at 20,000 g at 4*C. An aliquot of the supernatant was then allowed to react with 25 a solution of tetra-methyl-benzidine (16 mM) and 1 mM hydrogen peroxide. The rate of change in absorbance was measured by a spectrophotometer at 650 nm. MPO activity was defined as the quantity of enzyme degrading 1 pmol of peroxide/min at 370C and was expressed in units per gram weight of wet tissue. 30 Malondialdehyde (MDA) measurement C\NRPonbl\DCC\AMC4225446_[.DOC-21/03/2 12 - 15 The levels of MDA in the ileum and colon were determined as an indicator of lipid peroxidation (29). At the specified time point the ileum and the colon were removed, weighed and homogenised in 1.15% KCI solution. An aliquot (100 pl) of the homogenate was added to a reaction mixture containing 200 pl of 8.1% SDS, 1500 pl of 20% acetic acid (pH 3.5), 1500 pl of 0.8% thiobarbituric acid and 700 pl 5 distilled water. Samples were then boiled for 1 h at 95* C and centrifuged at 3,000 x g for 10 min. The absorbance of the supernatant was measured by spectrophotometry at 650 nm. Measurement of cytokines The levels of TNF-a and IL-1 P were evaluated in the plasma collected 60 min after reperfusion in the 10 SAO model and in the colon tissues at 4 days after intra-colonic injection of DNBS. The assay was carried out by using a colorimetric, commercial kit (Calbiochem-Novabiochem Corporation, USA). The ELISA (Enzyme-Linked Immunosorbent Assay) has a lower detection limit of 5 pg/ml. Materials. 15 Biotin blocking kit, biotin-conjugated goat anti-rabbit IgG and avidin-biotin peroxidase complex were obtained from Vector Laboratories (Burlingame, CA, USA). Primary anti-nitrotyrosine antibody was purchased from Upstate Biotech (Saranac Lake, NY). Primary ICAM-1 (CD54) was purchased from Pharmingen (DBA, Milan, Italy). All other reagents and compounds used were purchased from Sigma Chemical Company (Sigma, St. Louis, MO). 20 Data analysis All values in the figures and text are expressed as mean ± standard error (s.e.m.) of the mean of N observations. For the in vivo studies N represents the number of animals studied. In the experiments involving histology or immunohistochemistry, the figures shown are representative of at least three 25 experiments performed on different experimental days. The results were analysed by one-way ANOVA followed by a Bonferroni post-hoc test for multiple comparisons. A p-value less of than 0.05 was considered significant. Results 30 Protective effects of HDL in splanchnic artery occlusion shock C\NRPorblDCOAMC\4225446 I DOC-21rnV2012 - 16 Occlusion of the splanchnic arteries produced an increase in MAP, which then decreased until death occurred (Figure 1A). The mean survival time was found to be 74 ± 1.7 min, whereas control sham animals survived for the entire period of the experiment (Figure 11). Administration of recHDL significantly prevented the fall in blood pressure seen after reperfusion and increased the survival rate 5 (Figure 1). Having established the survival time, in another series of experiments, animals were sacrificed either after the period of ischaemia or 60 minutes post-reperfusion in order to collect blood and tissues for biochemical analysis. Reperfusion of the ischaemic splanchnic circulation led to the following events: a substantial increase in intestinal lipid peroxidation products as determined by increased levels of MDA (Figure 2A), TNF-a and IL-1p (Figure 3), and a profound infiltration of PMNs 10 into the intestine as determined by MPO activity (Figure 2B). Ileum sections collected from SAO shocked rats at 60 min of reperfusion showed an increase of positive staining for ICAM-1 along vessels and in the necrotic tissue (Figures 4A, 5A). These inflammatory events were triggered by the reperfusion phase since no changes were observed when blood or tissues were removed after the period of ischaemia alone (Figure 5A). recHDL (80 mg/kg), when given i.v. 30 min prior to ischaemia, 15 significantly inhibited the increased levels of MDA in the ileum (Figure 2A) as well as TNF-a and IL-1@ (Figure 3). HDL significantly reduced the PMN infiltration into the ileum (Figure 2B) and the up regulation of ICAM-1, which was expressed in the endothelium along the vascular wall (Figures 4B, 5A). Staining of ileum sections obtained from sham-operated rats with anti-ICAM-1 antibody showed a specific staining along vessels, demonstrating that ICAM-1 is constitutively expressed (Figure 5A). In 20 addition, ileum sections obtained from SAO-shocked rats at 60 min of reperfusion showed positive staining for nitrotyrosine (Figures 5A, 6A) and PAR (Figures 5A, 6C). Administration of recHDL reduced the degree of immunostaining for nitrotyrosine (Figure 5A, 6B) and PAR (Figure 5A, 6D) in the repressed intestine. No staining for either nitrotyrosine or PAR was observed in sham-operated rats (Figure 5A). Finally, histological examinations of the small intestine at 60 min post reperfusion (see 25 representative sections in Figure 7) revealed the following pathological changes: Ileum sections showed inflammatory infiltration by inflammatory cells extending through the wall and concentrated below the epithelial layer (Figure 7A). recHDL treated rats show a significant reduction in organ injury (Figure 7B). No histological alterations were observed in sham-treated rats (data not shown). 30 Protective effects of HDL in DNBS-induced colitis C :NRPorbl\DCAMC42254A6_ DOC.2 1A11121112 - 17 Four days after intra-colonic administration of DNBS, the colon appeared flaccid and filled with liquid stool. The macroscopic inspection of cecum, colon and rectum showed presence of mucosal congestion, erosion and haemorrhagic ulcerations (Figure 8A). The histopathological features included a transmural necrosis and oedema and a diffuse PMN cellular infiltrate in the submucosa (Figure 8B). 5 The inflammatory changes of the intestinal tract were associated with an increase in the weight of the colon (Figure 9A). Treatment of rats with recHDL (40 mg/kg/day) significantly attenuated the extent and severity of the histological signs of colon injury (Figures 8A, 8C). A significant increase in the weight of the spleen, an indicator of inflammation, was also noted in vehicle-treated rats, which had received DNBS (Figure 9B). No significant increase in weight of either colon or spleen was observed in 10 DNBS-rats, which had been treated with recHDL (Figure 9). The severe colitis caused by DNBS was associated with a significant loss in body weight (Figure 10A). Treatment of DNBS-rats with recHDL significantly reduced the loss in body weight (Figure 10A). Colonic injury by DNBS administration was also characterised by an increase of pro-inflammatory cytokines (TNF-a, and IL-1@) in the colon (Figure 10B). recHDL treatment reduced the increase in TNF-a and IL-1s as observed in colonic 15 tissues (Figure 108). At 4 days after DNBS treatment, sections of colon from sham-administered rats did not stain for either nitrotyrosine or PAR (Figure 5B). Colon sections obtained from vehicle-treated DNBS rats exhibited positive staining for nitrotyrosine (Figure 11A) and PAR (Figure 11C), which was localised in 20 inflammatory cells and in disrupted epithelial cells. recHDL treatment reduced the degree of immunostaining for nitrotyrosine (Figure 11B) and PAR (Figure 11D) in the colon of DNBS-treated rats. The presence of nitrotyrosine staining in the colon correlated positively with the increase in tissue levels of MDA, indicating an increase in lipid peroxidation (Figure 12A). recHDL treatment significantly reduced the degree of lipid peroxidation (determined as a decrease in tissue MDA levels, Figure 12A). 25 The colitis caused by DNBS was also characterised by an increase in MPO activity (Figure 12B). This finding is consistent with the observation made with light microscopy that the colon of vehicle-treated DNBS rats contained a large number of PMNs. Infiltration of PMNs into the mucosa has been suggested to contribute significantly to the tissue necrosis and mucosal dysfunction associated with colitis, as activated PMNs release large amounts of free radicals. To further elucidate the effect of 30 recHDL treatment on PMN accumulation in the inflamed colon, we next evaluated the intestinal expression of ICAM-1. Tissue sections obtained from sham-operated rats with anti-ICAM-1 antibody C \NRPorbhlDCC\AMC\4225446_ I DOC.21/M1/2012 - 18 showed a specific staining along the vessels, demonstrating that ICAM-1 is expressed constitutively in endothelial cells (Figure 5B). After DNBS administration, the staining intensity substantially increased in the vessels of the lamina propria and submucosa. Immunohistochemical staining for ICAM-1 was also present in epithelial cells of injured colon and in infiltrated inflammatory cells in damaged tissues 5 from DNBS-treated rats (Figure 13B). Treatment of DNBS-rats with recHDL, however, significantly reduced both the degree of PMN infiltration (determined as a decrease in MPO activity, Figure 12B) and the up-regulation of the constitutive ICAM-1, which was normally expressed in the endothelium along the vascular wall (Figure 13B). 10 Discussion This study provides evidence that treatment of rats with recHDL attenuates: (i) the development of SAO shock, (ii) the infiltration of the ileum with PMNs (histology and MPO activity), (iii) the degree of lipid peroxidation in the ileum, and (iv) the degree of ileum injury (histology) caused by ischaemia and reperfusion; (v) the development of DNBS-induced colitis, (vi) the infiltration of the colon with PMNs 15 (histology and MPO activity), (vii) the degree of lipid peroxidation in the colon, and (viii) the degree of colon injury (histology) in rats treated with DNBS. All of these findings support the view that recHDL attenuates the degree of gut inflammation in the rat. HDL reduces oxidative and nitrosative damage associated with gut ischaemia and with DNBS 20 induced colitis Reactive oxygen and nitrogen species play a key role in gut injury associated with IhR (12,13,30) and with IBD (14,31). The important contribution to the pathophysiology of IBD of reactive oxygen or nitrogen species has been demonstrated in both animal and clinical studies. These species are cytotoxic agents, inducing lipid peroxidation and other cellular oxidative stress by cross linking 25 proteins, lipids, and nucleic acids, which then cause cellular dysfunction, damage, and eventually death. Evidence consistent with damage caused by reactive radical species is provided by a large number of animal and clinical studies (12,13,30,31). In the present study, it has been found that the intestinal damage induced either by 1/R or by intra-colonic administration of DNBS was associated with high concentrations of MDA, which is considered a good indicator of lipid peroxidation (29). Recent 30 evidence indicates that nitration of tyrosine can result from a number of chemical actions, and can be considered as a global marker of nitrosative stress (32). Nitrotyrosine can be formed from the reaction C:\RPonbl\DCC\AMC\422544,_I DOC.2Ifl1/2)12 - 19 of nitrite with hypochlorous acid or the reaction of nitrite with MPO and hydrogen peroxide (33). In these experiments, increased immunohistochemical expression of nitrotyrosine has been found mostly localised on epithelial cells and in the area of infiltrated inflammatory cells, suggesting that peroxynitrite or other nitrogen derivatives and oxidants are formed in vivo and may contribute to tissue injury. These 5 data are consistent with previous findings that immunohistochemical staining for nitrotyrosine was localised on inflammatory cells during DNBS-induced colitis (34) and during SAO-shock (13,27). The pathogenic role of nitrogen derived species such as peroxynitrite (35) in gut inflammation is further supported by the fact that intra-colonic administration of exogenous peroxynitrite induces a severe colonic inflammation, which mimics the features of both ulcerative colitis and Crohn's disease. 10 In the present study it was observed that ileum and colon injury was significantly less in rats treated with recHDL. Indeed, HDL treatment prevented the formation of tissue MDA and nitrotyrosine staining in SAO-shocked rats and DNBS-treated animals. ROS [reactive oxygen species] cause DNA single strand damage, leading to PARP activation and cell death (36). Some evidence exists to support the possible role of PARP activation in the pathophysiology of gut inflammation (37). recHDL treatment 15 reduced PAR formation, an index of PARP activation, and this effect may well contribute to the overall protective effects of HDLs observed in these studies. The beneficial effect of HDLs in SAO- shock and in DNBS-induced colitis is related to an inhibition of cytokines production 20 TNF-a and IL-1p are clearly involved in the pathogenesis of I/R and colitis and these cytokines are present in the colon during inflammation (13,27,38). Direct evidence that TNF-a and IL-1p play a role in the pathogenesis of experimental colitis and SAO-shock has been obtained in animal models in which blocking of the action of these cytokines has been shown to delay the onset of gut injury and suppress the associated inflammatory response (13,27). A role for TNF-a in human disease came from 25 recent studies using Infliximab (38), a chimeric anti-TNF antibody, and CDP571, a humanised monoclonal antibody to TNF-a, and membrane-bound TNF without fixing complement nor mediating antibody-dependent cellular cytotoxicity (40). In both cases, significant reduction in Crohn's disease activity index (CDAI) as well as attenuation of histopathological and endoscopic inflammation in Crohn's disease patients was observed. 30 C:\NRPobI\DCC\AMC\4225446_ I DOC-2 Ilm/2012 - 20 As the present study demonstrates that recHDL significantly reduces the release of TNF-a and IL-1p associated with SAO-shock and with DNBS-induced colitis, and without wishing to be bound by any one theory, it is postulated by the present inventors that the inhibition of the formation of TNF-a and IL-11p plays an important role in the overall beneficial effects observed with HDL. These results are in 5 agreement with previous observations, which show that HDL also attenuates the release of pro inflammatory cytokines (including TNF-a) caused by small doses of intravenously administered LPS (10). The beneficial effects of HDL in SAO- shock and in DNBS-induced colitis are related to an 10 alteration in PMN recruitment. PMNs play a crucial role in the development and full manifestation of gastrointestinal inflammation, as they represent a major source of free radicals in the inflamed intestinal mucosa (41). PMN infiltration into inflamed tissues plays a crucial role in the destruction of foreign antigens and in the breakdown and remodelling of injured tissue (42). The interactions of PMNs with the endothelium are regulated by 15 various adhesion molecules including the selectins, the Beta2 integrins and adhesion molecules of the immunoglobulin superfamily (43). A firm adherence of the PMN to the endothelial surface is required for transendothelial migration (21). This firm adherence involves the interaction of Beta2 integrins (i.e., CD1 1/CD18) on the PMN surface and ICAM-1 on the endothelial cell surface (44). 20 A major finding of this study was that, not only did the recHDL-treated rats show a remarkable recovery of the intestinal injury associated with a reduction in oxidative and nitrosative damage after 1/R as well as after DNBS administration, but also in recHDL-treated rats, infiltration of PMNs into the colon was significantly reduced. Furthermore, ICAM-1 was expressed in endothelial and epithelial cells, and PMNs both in the ileum from SAO-shocked rats and in the distal colon from DNBS-treated rats. 25 recHDL treatment was associated with a significant reduction of ICAM-1 expression in endothelial and epithelial cells. These results clearly demonstrate that recHDLs can interrupt the cascade of events leading to the interaction between PMNs and endothelial cells in the late firm adhesion phase mediated by ICAM-1, and these findings are in agreement with other previously published studies (9,10). 30 C.\NRPorblDCCAMC\4225446 I DOC-2 IA/2012 -21 Conclusions These results clearly demonstrate that recHDLs are protective in SAO-shock and in experimental colitis, and that inhibition of TNF-a and IL-1P formation (amongst other effects which include inhibition of PMN infiltration) in the injured tissue probably accounts for the beneficial effects. 5 The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates, 10 C, NRPonblCC\&AMC\225446_ DOC-213/21112 - 22 References: 1. Cockerill GW, Reed S: High-density lipoprotein: Multipotent effects on cells of the vasculature. Int. Rev. Cytol. 188: 257-297, 1999. 2. Nanjee MN, Doran JE, Lerch PG, Miller NE: Acute effects of intravenous infusion of apolipoprotein A-l/phosphatidylcholine discs on plasma lipoproteins in human. Arterioscler. Thromb. Vasc. Biol. 19: 979-989, 1999. 3. Gordon DJ, Probsfield JL, Garrison RJ: High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79:8 -15 989. 4. Paszty C, Maeda N, Verstuyft J: Apolipoprotein Al transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94: 899 -903, 1998. 5. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ: Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-1 in mice. Circulation 100: 1816-1822, 1999. 6. McDonald MC, Dhadly P, Cockerill GW, Cuzzocrea S, Mota-Filipe H, Hinds CJ, Miller NE, Thiemermann C. Reconstituted High-Density Lipoprotein Attenuates Organ Injury and Adhesion Molecule Expression in a Rodent Model of Endotoxic Shock. Shock. 20: 551-557, 2003. 7. Cockerill GW, McDonald MC, Mota-Filipe H, Cuzzocrea S, Miller NE, Thiemermann C: High density lipoproteins reduce organ injury and organ dysfunction in a rat model of haemorrhagic shock. FASEB J. 15: 1941-1952, 2001. 8. Van Leeuwen HJ, van Beek AP, Dallinga-Thie GM, van Strijp JA, Verhoef J, van Kessel KP: The role of high density lipoprotein in sepsis. Neth. J. Med. 59: 102-110, 2001. 9. Cockerill GW, Huehns TY, Miller NE, C Lerch PG, Miller NE, Haskard DO: Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 103: 108-112, 2001. 10. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJ: Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxaemia. J. Exp. Med. 184:1601-1608, 1996. 11. Thiemermann C, Patel NSA, Kvale EO, Cockerill GW, Brown PA, Stewart KN, Cuzzocrea S, Britti D, Mota-Filipe H, Chatterjee PK: High density lipoprotein (HDL) reduces renal ischaemia/reperfusion injury. J. Am. Soc. Nephrol. 14: 1833-43, 2003.

C\NRPobl\DCC'\AMC\4225446_j DOC-21/I3/2012 - 23 12. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischaemia/reperfusion injury. Pharmacol. Rev. 53: 135 59, 2001. 13. Cuzzocrea S, Chatterjee PK, Mazzon E, Dugo L, De Sarro A, Van de Loo FA, Caputi AP, Thiemermann C. Role of induced nitric oxide in the initiation of the inflammatory response after postischemic injury. Shock. 18:169-76, 2002. 14. Cuzzocrea S, Mazzon E, Dugo L, Caputi AP, Riley DP, Salvemini D: Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis. Eur. J. Pharmacol. 43: 79-89, 2001. 15. Parks DA: Oxygen radicals: mediators of gastrointestinal pathophysiology. Gut 30: 293-298, 1989. 16. Kitahora, T., Suzuki, K., Asakura, H., Yoshida, T., Suematsu, M., Watanabe, M., Aiso, S., Tsuchiya, M. (1988) Active oxygen species generated monocytes and polymorphonuclear cells in Crohn's disease. Dig. Dis. Sci. 33, 951 -955. 17. Mahida YR, Wu KC, Jewell DP: Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease. Gut 30: 1362- 1370, 1989. 18. Verspaget HW, Pena AS, Weterman IT, Lamers CB: Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content. Gut 29: 223-228, 1988. 19. Crama-Bohbouth GE, Arndt JW, Pena AS, Verspaget HW, Tjon A Tham RT, Weterman IT, Pauwels EK, Lamers CB: Value of indium-1 11 granulocyte scintigraphy in the assessment of Crohn's disease of the small intestine: prospective investigation. Digestion 40: 227-236, 1988. 20. Grisham MB, Granger D: N. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig. Dis. Sci. 33: 6-15, 1988. 21. Butcher EC: Specificity of leukocyte-endothelial interactions and diapedesis: physiologic and therapeutic implications of an active decision process. Res. Immunol. 144: 695-698, 1993. 22. Wertheimer SJ, Myers CL, Wallace RW, Parks TP: Intercellular adhesion molecule-1 gene expression in human endothelial cells. J. Biol. Chem. 267: 12030-12035, 1992. 23. Wallace JL, Keenan CM, Gale D, Shoupe TS: Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related elevated leukotriene 84 synthesis. Gastroenterology 1: 18-27, 1992.

C \NRPorlbl\DCC\AMC4225446_1 DOC-2/1/3/202 - 24 24. Matz, C. E., Jonas, A. Micellar complexes of human apolipoprotein A-1 with phosphatidyicholines and cholesterol prepared from cholate-lipid dispersion. J. Biol. Chem. 257: 4535-4540, 1982. 25. Lerch, P. G., Fortsch, V., Hodler, G., Bolli, R. Production and characterisation of a reconstituted high-density lipoprotein for therapeutic applications. Vox Sang 71: 155-164, 1996. 26. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten induced model of chronic inflammation and ulceration in the rat. Gastroenterology 96: 795-803, 1989. 27. Cuzzocrea S, Misko TP, Costantino G, E Micali A, Caputi AP, Macarthur H, Salvemini D: Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion. FASEB J. 14: 1061-72, 2000. 28. Mullane KM, Kraemer R, Smith B: Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischaemic myocardium. J. Pharmacol. Meth. 14:157-167, 1985. 29. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95: 351-358, 1979. 30. Cuzzocrea S, McDonald MC, Mazzon E, Filipe HM, Costantino G, Caputi AP, Thiemermann C. Beneficial effects of tempol, a membrane-permeable radical scavenger, in a rodent model of splanchnic artery occlusion and reperfusion. Shock. 14:150-6, 2000. 31. Grisham MB: Oxidants and free radicals in inflammatory bowel disease. Lancet 344: 859-861, 1994. 32. Halliwell B: What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett. 411: 157-160, 1997. 33. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van der Vlie A: Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391, 393-397, 1998. 34. Cuzzocrea S, McDonald MC, Mazzon E, Mota-Filipe H, Centorrino T, Terranova ML, Ciccolo A, Britti D, Caputi AP, Thiemerman C: Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. Gut 48: 478-88, 2001. 35. Ischiropoulos H, Zhu L, Beckman JS: Peroxynitrite formation from microphage-derived nitric oxide. Arch. Biochem. Biophys. 298: 446-451, 1992.

C:\R PonbrlDCC\AMC4225446_1. DOC-21A/U2012 -25 36. Szab6 C, Dawson VL: Role of poly(ADP-ribose) synthetase in inflammation and ischaemiareperfusion. Trends Pharmacol. Sci. 19:287-298, 1998. 37. Mazzon E, Dugo L, De SA, Li JH, Caputi AP, Zhang J, Cuzzocrea S. Beneficial effects of GPI 6150, an inhibitor of poly(ADP-ribose) polymerase in a rat model of splanchnic artery occlusion and reperfusion. Shock. 17:222-7, 2002. 38. Grotz MR, Ding J, Guo W, Huang Q, Deitch EA. Comparison of plasma cytokine levels in rats subjected to superior mesenteric artery occlusion or haemorrhagic shock. Shock. 3:362-8, 1995. 39. Present DH, Rutgeerts P, Targan S, SB Mayer L, van Hogez and RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340: 1398-1405, 1999. 40. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA: Randomized controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn's disease. Lancet 349: 521-524, 1997. 41. Grisham MB: Oxidants and free radicals in inflammatory bowel disease. Lancet 344: 859-861, 1994. 42. Lefer AM, Lefer DJ: Pharmacology of the endothelium in ischaemia-reperfusion and circulatory shock. Ann. Rev. Pharmacol. Toxicol. 33: 71-90, 1993. 43. Geng JG, Bevilacqua MP, Moore KL: Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 343: 757-760, 1990. 44. Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK: Expression of vascular adhesion molecules in inflammatory bowel. Gastroenterology 103:840-847, 1992.

Claims (21)

1. A method for the treatment and/or prophylaxis of inflammatory bowel disease in a patient, which comprises parenteral administration to said patient of an effective amount of high density lipoprotein (HDL).

2. The method of claim 1, wherein said patient is a human.

3. The method of claim 1 or claim 2, wherein said HDL is selected from the group consisting of nascent HDL, reconstituted HDL, recombinant HDL and a functional peptide or other analogue thereof.

4. The method of claim 3, wherein said HDL is reconstituted HDL.

5. The method of claim 3, wherein said HDL is nascent HDL.

6. The method of claim 3, wherein said HDL is recombinant HDL.

7. The method of any one of claims 1 to 6, wherein said HDL is administered in a dosage range of from 0.1-200 mg per kg body weight of the patient per treatment.

8. The method of claim 7, wherein said HDL is administered in a dosage range of from 10-80 mg per kg body weight per treatment.

9. The method of any one of claims 1 to 8, wherein said parenteral administration is selected from the group consisting of intravenous, intraarterial, intramuscular and subcutaneous injection or infusion.

10. The method of claim 9, wherein said parenteral administration is intravenous injection or infusion.

11. The use of high density lipoprotein (HDL) in the manufacture of a medicament for parenteral C:\NRPorbl\DCC\AMC\1225446_ I DOC-2 113/2012 - 27 administration to a patient for the treatment and/or prophylaxis of inflammatory bowel disease in said patient.

12. The use of claim 11, wherein said patient is a human.

13. The use of claim 11 or claim 12, wherein said HDL is selected from the group consisting of nascent HDL, reconstituted HDL, recombinant HDL and a functional peptide or other analogue thereof.

14. The use of claim 13, wherein said HDL is reconstituted HDL.

15. The use of claim 13, wherein said HDL is nascent HDL.

16. The use of claim 13, wherein said HDL is recombinant HDL.

17. The use of any one of claims 11 to 16, wherein said HDL is administered in a dosage range of from 0.1-200 mg per kg body weight of the patient per treatment.

18. The use of claim 17, wherein said HDL is administered in a dosage range of from 10-80 mg per kg body weight per treatment.

19. The use of any one of claims 11 to 18, wherein said parenteral administration is selected from the group consisting of intravenous, intraarterial, intramuscular and subcutaneous injection or infusion.

20. The use of claim 19, wherein said parenteral administration is intravenous injection or infusion.

21. The method of claim 1, or the use of claim 11, substantially as hereinbefore described with reference to the Examples and the accompanying drawings.